- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Oneness Biotech Co., Ltd., Nanchou Plant had been granted with Medical Devices Quality Management System (QMS) Approval.
Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in New Zealand.
Oneness Board of Directors resolved to convene the Annual Shareholders' Meeting of 2023.(additional matters)
The board of directors of Oneness approved a resolution on issuance of the Restricted Stock Awards (RSA) of 2023.
The Board of Directors resolved to the new common share issuance through the increase of capital by capitalization of earnings and capital surplus
The Board of Directors resolved to distribute dividends.
The Company's 2022 consolidated financial statements have been approved by the Board of Directors
Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in India.
Oneness Awarded Industry Mover in the S&P Global Sustainability Yearbook 2023
Oneness Board of Directors resolved to convene the Annual Shareholders' Meeting of 2023.
Oneness received new drug approval by Singapore HSA on its DFU new drug, FESPIXON.
Oneness has been included in the Bloomberg Gender Equality Index for two consecutive years
An U.S. patent titled "METHOD FOR PREPARING PLECTRANTHUS AMBOINICUS FRACTION HAVING ANTI-ARTHRITIS ACTIVITY" has been granted.
The CEA of Fespixon based on its significant clinical efficacy showed its cost-effectiveness for treating DFUs. The manuscript was published by JAMA Network Open
The exploratory trial result of Fespixon in improving postoperative scar cosmesis has been published by a renowned SCI journal, Aesthetic Surgery Journal.